CAR T-Cell Therapy: High Response Rates, High Toxicity Rates

Adults 6

CAR T-cell therapy has drastically changed the treatment landscape of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) – a patient population that traditionally has been difficult to treat and had poor outcomes.

“CAR T-cell represents new treatment for diffuse large B-cell lymphoma in the relapsed/refractory setting,” said Andrew D. Zelenetz, MD, PhD, medical oncologist and medical director of quality informatics at Memorial Sloan Kettering Cancer Center. “As a result, it’s been included in the NCCN guidelines for transformed follicular lymphoma, transformed marginal zone lymphoma, and for diffuse large B-cell lymphoma, as well as refractory diffuse large B-cell lymphoma.”

Zelenetz recently discussed CAR T-cell therapy for this patient population at the NCCN 2020 Virtual Congress on Hematologic Malignancies.

Read the full article featured in Oncology Nursing News, here.

Last Updated on Thursday 26 November 2020.